← Inspire Medical Systems, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | ($17.5m) |
($21.8m)
-24.65%
|
($33.2m)
-52.30%
|
($57.2m)
-72.08%
|
($42.0m)
+26.50%
|
($44.9m)
-6.75%
|
($21.2m)
+52.87%
|
$53.5m
+352.96%
|
$145.4m
+171.77%
|
— | |
| Depreciation and amortization | $285k | $393k | $495k | $840k | $1.2m | $1.9m | $2.8m | $6.5m | $14.0m | $17.2m | |
| Deferred income taxes (benefit) | — | — | — | — | — | — | $0 | $0 | ($88.7m) | ($77.6m) | |
| Stock-based compensation expense | $243k | $1.2m | $6.2m | $12.8m | $26.2m | $52.0m | $82.5m | $116.0m | $130.3m | $119.4m | |
| Impairment of strategic investment | — | — | — | — | — | — | $0 | $0 | $4.0m | — | |
| Accounts receivable | ($1.8m) | ($2.8m) | ($6.5m) | ($11.8m) | ($9.2m) | ($27.0m) | ($30.2m) | ($2.6m) | ($26.2m) | $34.3m | |
| Inventories | ($315k) | $1.0m | ($3.2m) | ($2.6m) | ($8.8m) | $5.3m | ($22.0m) | ($46.2m) | ($65.2m) | ($48.8m) | |
| Accounts payable | $1.8m | $439k | $1.0m | $2.0m | $4.8m | $14.4m | $9.3m | $604k | ($3.7m) | ($22.3m) | |
| Property and equipment included in accounts payable and accrued expenses | — | $0 | $0 | $816k | $274k | $2.1m | $4.0m | $3.4m | $4.8m | — | |
| Accrued expenses and other liabilities | $1.3m | $3.6m | $2.9m | $1.1m | $7.1m | $11.9m | $6.9m | $12.9m | $6.1m | — | |
| Excise taxes accrued but not paid | — | — | — | — | — | — | $0 | $0 | $1.0m | — | |
| Prepaid expenses and other current assets | ($308k) | ($1.3m) | ($905k) | $416k | ($696k) | ($2.8m) | ($4.8m) | ($2.3m) | $1.7m | — | |
| Net cash provided by operating activities | ($15.8m) |
($18.7m)
-18.38%
|
($32.8m)
-75.70%
|
($53.0m)
-61.50%
|
($20.1m)
+62.07%
|
$11.6m
+157.50%
|
$24.7m
+113.10%
|
$130.2m
+428.32%
|
$117.0m
-10.19%
|
$157.1m
+34.28%
|
|
| Purchases of property and equipment | ($412k) | ($250k) | ($2.7m) | ($2.5m) | ($4.7m) | ($9.1m) | ($23.6m) | ($39.1m) | ($38.5m) | ($40.0m) | |
| Purchases of investments | ($9.0m) | ($115.5m) | ($178.1m) | ($52.7m) | ($10.0m) | $0 | ($281.2m) | ($418.4m) | ($240.3m) | — | |
| Proceeds from sales or maturities of investments | $1.8m | $32.3m | $137.3m | $141.8m | $43.8m | $0 | $10.2m | $344.6m | $310.4m | — | |
| Purchases of strategic investments | — | — | — | $0 | $0 | ($10.5m) | ($250k) | ($250k) | ($10.1m) | — | |
| Net cash provided by (used in) investing activities | ($7.6m) | ($83.4m) | ($43.6m) | $86.6m | $29.1m | ($19.6m) | ($294.8m) | ($113.1m) | $21.4m | ($31.3m) | |
| Accelerated share repurchase of common stock | — | — | — | — | — | — | $0 | ($75.0m) | $0 | — | |
| Share repurchase of common stock | — | — | — | — | — | $0 | $0 | ($75.0m) | ($175.0m) | — | |
| Proceeds from the issuance of common stock from employee stock purchase plan | $0 | $0 | $1.4m | $2.4m | $3.5m | $3.7m | $5.3m | $5.6m | $5.0m | — | |
| Payment of taxes on net share settlement of equity awards | — | — | — | $0 | $0 | ($43k) | ($17.2m) | ($5.2m) | ($23.0m) | — | |
| Net cash (used in) provided by financing activities | $25.7m |
$190.4m
+641.92%
|
$2.0m
-98.97%
|
$134.1m
+6726.12%
|
$14.9m
-88.85%
|
$235.1m
+1472.63%
|
$13.9m
-94.07%
|
($52.4m)
-475.58%
|
($183.4m)
-250.14%
|
— | |
| Cash and cash equivalents at beginning of year | $9.0m | $97.3m | $22.9m | $190.5m | $214.5m | $441.6m | $185.5m | $150.2m | $104.8m | $106.9m | |
| Effect of exchange rate on cash | $0 | $33k | $13k | $11k | ($19k) | $75k | $164k | ($118k) | ($310k) | ($17k) | |
| Additional Supplementary Disclosures | |||||||||||
| Additional Supplementary Disclosures | |||||||||||
| Accretion of investment discount | $0 | ($648k) | ($983k) | ($22k) | $14k | ($4k) | ($2.5m) | ($8.9m) | ($2.9m) | — | |
| Provision (benefit) for estimated credit losses | — | — | — | — | — | ($63k) | $1.6m | ($768k) | $200k | — | |
| Other non-cash expenses | — | — | — | — | — | $879k | $2.1m | $1.5m | $2.1m | — | |
| Proceeds from the exercise of stock options | $235k | $558k | $1.1m | $7.0m | $11.5m | $12.1m | $25.8m | $22.2m | $9.6m | — | |
| Decrease in cash and cash equivalents | $2.3m | $88.3m | ($74.4m) | $167.7m | $23.9m | $227.1m | ($256.1m) | ($35.4m) | ($45.3m) | — | |
| Cash paid for interest | $1.3m | $2.0m | $2.0m | $1.9m | $1.9m | $2.3m | $0 | $22k | $137k | — |